Pharming Group (PHAR)
(Delayed Data from NSDQ)
$8.60 USD
0.00 (0.04%)
Updated Jun 14, 2024 03:59 PM ET
After-Market: $8.16 -0.44 (-5.12%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Brokerage Reports
Pharming Group N.V. Sponsored ADR [PHAR]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q24 Results; Leniolisib Traction Continuing to Increase Nicely as Ruconest Remains Core
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Phase 3 Assessing Leniolisib in Pediatric Population Completes Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2023 Results; Revenues, Shopping, and Solid Foundations, Oh My; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Ruconest Outperforms and Joenja Continues Strong Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib Plots New Course to Expand Therapeutic Reach Into PIDs; Phase 2 Start Planned for 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Second Pediatric Phase 3 Trial of Leniolisib in APDS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib''s Global Footprint Begins to Grow; European MAA Decision Could Come as Early as 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Product Revenues Beat; Looking For New Joenja Territories and Indications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib Sets Foot in Asia; Phase 3 APDS Trial Up and Enrolling in Japan
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q23 Results; Strong Joenja Launch; Focus On Expanding to Key Global Markets
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q23 Results; Joenja Commercial Launch Starts Off Strong; European Regulatory Decision Expected 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Bringing Balance to the Force; Joenja Approved as First APDS Rx; PRV Cash Could be Inbound
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2022 Results; Leniolisib Approaches Finish Line; PDUFA Date March 29, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in First Pediatric APDS Trial of Leniolisib; PDUFA Date for Adults and Adolescents March 29
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
EMA Downshifts Leniolisib''s Review; PDUFA Date Remains on Track for March 29, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
OLE Study Supports Positive Phase 2/3 Data of Leniolisib in APDS; March 29, 2023 PDUFA ; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Another Regulatory Feather in the Cap; Accelerated Assessment For Leniolisib; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
3Q22 Results; Busy Times With Core Ruconest Growth and Leniolisib PDUFA March 29, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib Clears Important Next Step Towards Approval in EEA; MAA Submitted, Authorization Anticipated 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Priority Review For Leniolisib; Moving Toward Commercialization Backed by Robust Phase 2/3 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J